IXR1 Antibody

What is IXR1 and what are its key structural features?

IXR1 is a Saccharomyces cerevisiae transcriptional factor that belongs to the high mobility group box (HMGB) family of proteins. Its structure includes two in-tandem HMG-box domains arranged in the characteristic L-shaped architecture that is typical of this protein family . Each domain enables DNA binding through different mechanisms, with differential binding between these domains explaining the protein's ability to recognize both specific cis-regulatory sequences and damaged DNA .

The NH2-terminal region contains the transcriptional activator domain, as identified in recent studies . IXR1 also possesses structural homology to the SOX family of transcriptional factors found in metazoans, which are crucial for tissue homeostasis, organogenesis, and cell fate determination during development . This structural conservation underscores the evolutionary importance of IXR1-like proteins across species.

What are the primary cellular functions of IXR1?

IXR1 exhibits multiple important cellular functions:

• Transcriptional regulation: IXR1 functions as both an activator and repressor of transcription on different promoters, particularly those involved in hypoxic responses . It extensively regulates the cellular adaptation to low oxygen conditions.

• DNA repair mechanism involvement: IXR1 participates in DNA repair processes and has been shown to bind to DNA-cisplatin adducts, similar to its human homologs HMGB1 and HMGB2 .

• Hypoxic stress response: IXR1 controls the expression of genes such as ROX1 and HEM13 by binding to specific DNA sequences in their promoters . This regulatory network helps yeast cells adapt to changing oxygen availability.

• Post-translational regulation: IXR1 undergoes differential phosphorylation depending on oxygen availability, suggesting sophisticated regulation of its activity under varied environmental conditions .

How does IXR1 function in transcriptional regulation?

IXR1's transcriptional regulatory function operates through several mechanisms:

• Dual regulatory activity: IXR1 can function as both an activator and a repressor depending on the target promoter context . This versatility allows for nuanced control of gene expression patterns.

• Domain-specific interactions: The NH2-terminal region of IXR1 contains its transcriptional activation domain, while other regions mediate repressive functions .

• Protein-protein interactions: Interactome studies have shown that IXR1 binds to Ssn8, which might mediate the repressor function of IXR1 on several promoters . This interaction represents one of the mechanisms through which IXR1 exerts its transcriptional control.

• DNA binding specificity: IXR1 recognizes and binds to specific DNA sequences in promoters such as ROX1 and HEM13 through its HMG-box domains . This sequence-specific binding is crucial for targeted gene regulation.

• Oxygen-responsive activity: The transcriptional activity of IXR1 changes in response to oxygen availability, making it a key regulator of the hypoxic response in yeast .

What specific antibodies are available for IXR1 research?

Several antibodies have been developed for IXR1 research in Saccharomyces cerevisiae. Commercially available options include:

This antibody recognizes IXR1 protein (UniProt No. P33417) from baker's yeast and can be used in various experimental applications . When selecting an antibody for IXR1 research, it's important to consider:

• The specific strain of yeast being studied

• The experimental application (Western blot, immunoprecipitation, ChIP, etc.)

• The epitope recognized by the antibody

• Validation data available for the specific application

For experimental validation, antibody specificity can be confirmed using IXR1 knockout strains as negative controls, as demonstrated in other protein studies .

What experimental approaches are most effective for studying IXR1 interactions?

To study IXR1 protein interactions effectively, researchers have employed several complementary approaches:

• Yeast two-hybrid (Y2H) technology: This has been successfully used to test IXR1 interactions with factors involved in hypoxic response such as Cyc8, Tup1, and Ssn8 . Y2H provides a robust initial screening method to identify potential interaction partners.

• Co-purification and mass spectrometry: This approach extends the interactome analysis to the whole repertory of yeast proteins. Studies have identified interactions between IXR1 and proteins involved in glucose metabolism, stress response, and ribosome biogenesis .

• Immunoprecipitation: Using specific antibodies against IXR1 to pull down protein complexes followed by Western blot analysis with antibodies against suspected interaction partners .

• Differential phosphorylation analysis: Since IXR1 shows oxygen-dependent phosphorylation patterns, phosphoproteomic approaches can reveal how post-translational modifications affect interaction networks .

For optimal results, a multi-faceted approach is recommended, beginning with screening techniques like Y2H followed by validation through co-immunoprecipitation and functional assays.

How can researchers optimize immunoprecipitation protocols for IXR1 studies?

Optimizing immunoprecipitation (IP) protocols for IXR1 studies requires attention to several critical factors:

• Sample preparation: For yeast cells, optimization of lysis conditions is crucial. Spheroplasting followed by gentle lysis in non-denaturing buffers helps maintain protein-protein interactions while effectively solubilizing chromatin-associated proteins.

• Preservation of post-translational modifications: Include phosphatase inhibitors in all buffers since IXR1 undergoes differential phosphorylation depending on oxygen availability .

• Antibody validation: Validate antibody specificity using appropriate controls including IXR1 knockout strains to confirm absence of signal. Tissue prints probed with anti-protein antibodies can serve as controls for specificity, as demonstrated with other proteins .

• Cross-linking considerations: For transient interactions, mild formaldehyde cross-linking (0.1-0.3%) may help stabilize complexes. This is particularly important when studying DNA-protein or protein-protein interactions in chromatin contexts.

• Reciprocal co-immunoprecipitation: Confirm interactions by performing reciprocal experiments. As demonstrated with IRX proteins, if protein A co-immunoprecipitates protein B, then antibodies to protein B should also co-immunoprecipitate protein A in wild-type extracts .

• Verification in mutant backgrounds: Test interactions in mutant backgrounds to assess dependency on other components. For example, studies with IRX proteins showed that when one component was absent, the interaction between the other two was no longer detectable .

What are the methodological challenges in studying IXR1's dual role in transcription and DNA repair?

Investigating IXR1's dual functionality presents several methodological challenges:

• Distinguishing between functions: Since IXR1 participates in both transcriptional regulation and DNA repair, it can be challenging to separate these functions experimentally. Domain-specific mutations or truncations can help isolate the regions responsible for each function.

• Context-dependent activity: IXR1's activity changes based on cellular conditions, particularly oxygen availability . Experimental design must account for these variations by carefully controlling environmental conditions.

• Protein complex dynamics: Different protein complexes may form around IXR1 depending on its function. Mass spectrometry approaches after differential fractionation can help identify function-specific interaction partners.

• DNA binding specificity: IXR1 binds both regulatory sequences and damaged DNA. In-vitro binding assays with purified components can help determine the specific binding preferences for different DNA structures.

• Temporal regulation: The timing of IXR1 recruitment to different genomic locations may vary based on function. Time-course ChIP experiments following induction of DNA damage or hypoxia can provide insights into the temporal dynamics of IXR1 activity.

Addressing these challenges requires integrated approaches combining genetics, biochemistry, and molecular biology to dissect the multifunctional nature of IXR1.

How do post-translational modifications affect IXR1 function and antibody recognition?

Post-translational modifications (PTMs) of IXR1, particularly phosphorylation, significantly impact its function and can affect experimental outcomes:

• Functional impact: Differential phosphorylation of IXR1 has been observed depending on oxygen availability . These modifications likely alter IXR1's:

  • DNA binding affinity and specificity

  • Protein-protein interaction capacity

  • Subcellular localization

  • Stability and turnover rate

• Antibody recognition challenges: PTMs can affect epitope accessibility and antibody binding. When using antibodies for IXR1 detection:

  • Some antibodies may preferentially recognize specific modified forms

  • Quantitative comparisons across different conditions may be affected by variable PTM states

  • Treatment with phosphatases or other modifying enzymes prior to immunoblotting can determine if antibody recognition is modification-dependent

• Experimental considerations: To account for modification-dependent effects:

  • Include appropriate inhibitors (phosphatase inhibitors, deacetylase inhibitors) in lysis buffers

  • Compare results across different oxygen conditions known to affect IXR1 modification

  • Consider using modification-specific antibodies when studying hypoxia responses

  • Combine antibody-based detection with mass spectrometry to map specific modification sites

Understanding the relationship between IXR1 PTMs and experimental detection is essential for accurate data interpretation, particularly when studying oxygen-dependent processes.

What are the similarities and differences between IXR1 and human HMGB proteins?

IXR1 shares several key similarities with human HMGB proteins while maintaining distinct characteristics:

Similarities:

• Structural homology: Like human HMGB1 and HMGB2, IXR1 contains two in-tandem HMG-box domains folded in the characteristic L-shaped architecture .

• DNA binding properties: All these proteins can bind to DNA with a preference for distorted structures and cisplatin-damaged DNA .

• Dual functionality: Similar to IXR1, human HMGB proteins participate in both transcriptional regulation and DNA repair processes .

• DNA damage recognition: IXR1, HMGB1, and HMGB2 all can bind DNA-cisplatin adducts, suggesting conserved functions in DNA damage detection .

Differences:

• Cellular externalization: Unlike IXR1, human HMGB1 can be externalized from cells and function as an alarmin that activates immune responses by binding to receptors like RAGE and TLRs .

• Signaling functions: Human HMGB1 activates NF-κB signaling and participates in inflammatory responses, functions not documented for IXR1 .

• Post-translational modification patterns: While both undergo PTMs, the specific patterns and regulatory mechanisms differ.

• Evolutionary context: IXR1 functions in unicellular yeast, while human HMGB proteins operate in complex multicellular systems with specialized tissues and immune functions.

These similarities and differences make comparative studies between IXR1 and human HMGB proteins valuable for understanding the evolution of DNA-binding proteins and their diverse cellular functions.

How can IXR1 antibodies be used in chromatin immunoprecipitation studies?

Chromatin immunoprecipitation (ChIP) with IXR1 antibodies allows researchers to map genomic binding sites and understand transcriptional regulatory networks. For optimal ChIP experiments:

• Cross-linking optimization: Determine the optimal formaldehyde concentration (typically 1%) and cross-linking time to preserve IXR1-DNA interactions without creating excessive non-specific cross-links.

• Sonication parameters: Optimize sonication conditions to generate DNA fragments of 200-500 bp for high-resolution mapping of binding sites.

• Antibody selection: Use validated antibodies with demonstrated specificity for IXR1. Control experiments with IXR1 knockout strains help confirm antibody specificity .

• Known targets as positive controls: Include primers for known IXR1 binding sites such as ROX1 and HEM13 promoters as positive controls .

• Normalization strategy: Always process input samples alongside IP samples and normalize ChIP signals to account for differences in chromatin preparation.

• Oxygen condition considerations: Since IXR1 binding patterns change with oxygen availability, carefully control and document oxygen conditions during experiments .

• Sequential ChIP: For studying co-occupancy with other factors (e.g., Ssn8), consider sequential immunoprecipitations .

ChIP-seq approaches provide genome-wide binding profiles, while ChIP-qPCR is suitable for analyzing specific target regions with higher throughput.

What controls are essential when using IXR1 antibodies in experimental procedures?

When using IXR1 antibodies, several controls ensure experimental validity:

• Specificity controls:

  • Perform parallel experiments with IXR1 knockout strains to confirm absence of signal

  • Include isotype-matched IgG controls to assess non-specific binding

  • Use blocking peptides to demonstrate epitope specificity

• Expression analysis controls:

  • When analyzing tissue or cell prints, include serial prints probed with antibodies recognizing different proteins to compare expression patterns

  • The first prints from fresh cut faces ensure optimal protein detection

• Immunoprecipitation controls:

  • Perform control immunoprecipitations to demonstrate that target proteins are present in the extracts

  • Include reciprocal co-IPs (e.g., if IXR1 co-precipitates with protein X, then protein X should co-precipitate with IXR1)

• Mutant background controls:

  • Test interactions in relevant mutant backgrounds to assess dependency relationships

  • For example, studies with other proteins have shown that when one component is absent, interactions between remaining components may be disrupted

• Technical controls:

  • Include loading controls for Western blots

  • Perform technical replicates of quantitative measurements

  • Include spike-in controls for quantitative comparisons

Implementation of these controls helps distinguish genuine IXR1-specific signals from technical artifacts and provides confidence in experimental results.

How can researchers effectively study IXR1's role in cisplatin-induced DNA damage responses?

To investigate IXR1's involvement in cisplatin-induced DNA damage responses, researchers can employ several strategic approaches:

• In vitro binding assays: Use purified IXR1 protein and cisplatin-modified DNA oligonucleotides to assess direct binding affinity and specificity. Electrophoretic mobility shift assays (EMSA) can quantify these interactions.

• Cisplatin sensitivity assays: Compare survival rates of wild-type yeast versus IXR1 knockout strains after cisplatin treatment. Complementation with specific IXR1 mutants can identify domains critical for the DNA damage response.

• ChIP analysis after cisplatin treatment: Perform ChIP with IXR1 antibodies before and after cisplatin treatment to identify genomic regions where IXR1 is recruited following DNA damage .

• Interactome changes: Compare IXR1-interacting proteins in normal versus cisplatin-treated cells to identify damage-specific interactions. This approach has been successfully used with human HMGB1 in cancer cells treated with cisplatin .

• Domain-specific mutations: Create yeast strains expressing IXR1 with mutations in specific HMG-box domains to determine their differential roles in cisplatin damage recognition .

• Transcriptional profiling: Perform RNA-seq comparing wild-type and IXR1-deficient cells after cisplatin treatment to identify genes whose expression depends on IXR1 during DNA damage response.

These approaches, particularly when used in combination, can provide comprehensive insights into how IXR1 functions in the cellular response to cisplatin-induced DNA damage.

How can IXR1 research inform studies on human HMGB proteins in cancer therapy?

IXR1 research provides valuable insights that can inform studies on human HMGB proteins in cancer therapy:

• Mechanisms of cisplatin resistance: Understanding how IXR1 recognizes cisplatin-DNA adducts can reveal conserved mechanisms that may apply to human HMGB proteins. This knowledge is relevant for investigating cisplatin resistance in cancer, as cells activate mechanisms to evade chemotherapy-induced cell death pathways .

• Interactome analysis: Studies identifying IXR1-binding proteins offer potential targets for investigation in human cancer cells. The identification of HMGB1 or HMGB2-binding proteins associated with specific cancerous processes is an active area of translational cancer research .

• Regulatory network conservation: Pathways regulated by IXR1 in yeast may have functional equivalents in human cancer cells, particularly those involving hypoxic adaptation which is crucial in tumor microenvironments .

• Structure-function relationships: Insights into how specific domains of IXR1 mediate different functions can guide the development of targeted therapeutics that modulate specific activities of human HMGB proteins.

• Post-translational modification patterns: Understanding how PTMs regulate IXR1 function may reveal similar regulatory mechanisms for human HMGB proteins that could be therapeutically targeted .

The characterization of interactions between IXR1, HMGB1, and HMGB2 with other cellular proteins provides valuable knowledge that can be applied to future cancer diagnosis and treatment strategies, as well as in addressing mechanisms of resistance to platinum-derived drugs .

What genetic approaches are most effective for studying IXR1 function in vivo?

Several genetic approaches have proven effective for investigating IXR1 function in vivo:

These approaches are particularly powerful when combined with biochemical and cell biological methods to provide complementary insights into IXR1 function from multiple perspectives.

How can researchers leverage IXR1 to study hypoxic responses across species?

IXR1's central role in hypoxic responses makes it a valuable model for comparative studies across species:

• Complementation studies: Express human HMGB proteins in IXR1-deficient yeast to assess functional conservation. This approach can identify which aspects of hypoxic regulation are evolutionarily conserved.

• Domain swap experiments: Create chimeric proteins containing domains from IXR1 and human HMGB proteins to determine which regions are responsible for hypoxia-specific functions.

• Comparative genomics: Analyze the promoters of IXR1-regulated genes in yeast and compare with promoters of hypoxia-responsive genes in higher eukaryotes to identify conserved regulatory elements.

• Parallel interactome mapping: Compare the protein interaction networks of IXR1 in yeast with those of HMGB proteins in human cells under hypoxic conditions to identify conserved functional modules .

• Cellular response assays: Develop parallel assays measuring hypoxic responses in yeast and human cells to enable direct comparison of the regulatory networks.

• Metabolic profiling: Compare metabolic adaptations to hypoxia in IXR1-deficient yeast with those in cells lacking specific HMGB proteins to identify conserved metabolic pathways.

These comparative approaches can reveal fundamental principles of hypoxic adaptation that are conserved from yeast to humans, potentially identifying new therapeutic targets for conditions involving hypoxia, such as cancer, ischemic disease, and stroke.